Max Healthcare Institute LtdQ3 FY23
Max Healthcare Institute Ltd Q3 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,081P/E: 70.0Market Cap: ₹1.0L CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Occupied bed days grew 3% YoY and 5% QoQ with average occupancy at 77%; inpatient discharges up 7% YoY.
- →Network gross revenue increased 17% YoY, driven by ARPOB growth and higher occupied bed days.
- →Revenue from international business grew 25% YoY and 11% QoQ; international revenue now ~9% of hospital revenue.
- →Oncology specialty revenue growing faster (26%-28%) than overall business (17%), driven by higher disease burden and insurance penetration.
- →Capacity to expand with 2,600 beds coming online over next 3-4 years, adding significant growth runway.
- →Institutional business ARPOB up 28% YoY due to mix change rather than price hike.
- →Expect continued multi-decade growth opportunity due to under-penetration of quality healthcare in India.
- →EBITDA and cash flow expected to maintain robust growth trajectory with bed expansions and operational efficiencies.
Margin guidance
Category 3- →Expectation of continued strong revenue and EBITDA growth trajectory of around 20% per year over the next 3-5 years, supported by both organic expansion and inorganic opportunities.
- →Network EBITDA grew 20% year-on-year in H1 FY24, reflecting operational efficiencies and improved payor mix.
- →EBITDA per bed increased by 15% indicating improved profitability and operational leverage.
- →Upcoming capacity expansion of ~2,600 beds over the next 3-4 years, mostly brownfield projects with quick breakeven typically within 1-2 quarters, will drive higher cash flows and earnings growth.
- →The recent brownfield expansion (Shalimar Bagh) reported EBITDA growth of 48% year-on-year, showcasing strong margin expansion.
- →Continued improvement expected from payor mix upgrades, specialty focus (oncology growth of 26-28%), and international patient revenue growth.
- →Management highlights disciplined capital allocation to sustain 20%+ earnings growth and long-term value creation.
3 more insights locked — sign up free to unlock
Fundraise plans
- The management did not mention any immediate plans for fundraising through debt or equity during the call.
- They highlighted accumulating cash and being conscious of fiscal discipline in deployments.
- Cash and leverage capacity are viewed as limited relative to large acquisition opportunities available at high valuations (15-16X EV/EBITDA).
- They intend to deploy capital carefully, balancing expansion and acquisitions with fiscal prudence.
- No explicit mention of upcoming debt or equity issuance was made; instead, focus is on organic growth, brownfield expansions, and select acquisitions.
- The existing cash and balance sheet strength are considered adequate for near-term expansion, with plans to announce acquisitions soon.
Overall, no current or immediate new fundraising through debt or equity was disclosed.
Order book
- →The company has a significant development pipeline with 2,600 new beds coming up in the next few years.
- →Specific projects under progress include:
- → - 329 beds at Nanavati: Excavation and raft work complete; ground level structure expected to be finished within the current quarter.
- → - 300 beds at Sector 56, Gurgaon: Site excavation almost done; EPC contractor on board; project on schedule.
- → - 190 beds at Mohali: D-wall completed; excavation underway; statutory approvals all received; project on time.
- → - 350 beds at Max Smart, Saket: Delayed due to tree transplant permissions but work to commence from December 2023.
- → - 300 beds at Vikrant, Saket: Environmental clearance received; municipal submissions in process.
- → - 250 beds at Patparganj: Drawings submitted; environmental clearance application submitted.
- →All projects are progressing on schedule without delays.
- →No new project acquisitions have been added in the last two years, but the company is actively looking at 20+ cities for expansion, including acquisitions and partnerships, with expected announcements soon.
Capex plans
Yes- →Ongoing expansions include 2,600 beds with 300 beds expected by FY24-end and approximately 819 beds in FY25 (Nanavati 329 beds, Mohali 190 beds, Gurgaon 300 beds).
- →Max Shalimar Bagh brownfield expansion operational with 78% occupancy; brownfields have quick EBITDA breakeven (within quarter or two).
- →Greenfield projects comprise 10% of expansion with breakeven expected within 12 months.
- →Max Smart at Saket: 350 beds delayed but work to restart by Dec 2023.
- →Max Vikrant at Saket and Patparganj expansions progressing with approvals underway.
- →Strategic focus on fiscal discipline while deploying cash; acquisitions considered at right price but prefer built-to-suit, asset-light models over Greenfields.
- →Developer of Dwarka hospital (300 beds) applied for occupancy certificate, expected commissioning Q4 2023.
- →Planned capital deployment on both capacity expansion and inorganic opportunities; accumulation of cash with intent to invest soon.
How does Max Healthcare Institute Ltd rank vs peers in Healthcare Services?
Pro feature1Max Healthcare Institute Ltd
Rev 2Mar 3
See full Healthcare Services sector rankings
Want more stocks like Max Healthcare Institute Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio